Early Surgical Outcome of Esophagectomy Performed for Carcinoma Esophagus after Neoadjuvant Chemotherapy – a single center experience from Sub Himalayan region

Early Surgical Outcome of Esophagectomy Performed for Carcinoma Esophagus after Neoadjuvant Chemotherapy – a single center experience from Sub Himalayan region | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Early Surgical Outcome of Esophagectomy Performed for Carcinoma Esophagus after Neoadjuvant Chemotherapy – a single center experience from Sub Himalayan region Chiranjit Mukherjee, Sourabh Nandi, Anshika Arora, Sunil Saini, and 2 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-3610353/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Esophageal cancer poses a significant global health burden, characterized by high aggressiveness and mortality rates. Despite a decline in overall incidence, certain regions exhibit a rise of adenocarcinoma incidence. At present multimodality approach with neoadjuvant treatment (Chemotherapy, Radiotherapy or both) followed by surgery with or without adjuvant treatment is standard of care, although there is no standard protocol. This retrospective, conducted at a tertiary center in the Himalayan region, explores the outcomes of esophageal and gastroesophageal junctional cancer patients undergoing surgery following neoadjuvant chemotherapy. Among 106 patients, 87 received preoperative chemotherapy, with demographic data revealing a male predominance and prevalent squamous cell carcinoma histology. Neoadjuvant therapy mainly comprised taxane-platinum regimens, with subsequent surgical procedures predominantly Ivor Lewis or McKeown esophagectomies. 30-day morbidity and mortality were observed in 35.29% of cases, with nonsurgical complications, particularly respiratory issues, being the most common. Our study reported a complete pathological response in 12.5% cases and an R0 resection rate exceeding 93%. While acknowledging the study’s retrospective and non-randomized nature, these findings suggest that neoadjuvant chemotherapy facilitates safe esophageal cancer surgeries specifically in undernourished patients. 1. Introduction Esophageal cancer stands out as one of the most aggressive malignancies affecting the digestive tract, representing a prominent contributor to global cancer-related mortality [ 1 ]. Despite an overall downward trend in incidence, an increasing trend has been observed in some nations with high incidence ratios of Adenocarcinoma /Squamous Cell Carcinoma (SCC). [ 2 , 3 ] Overall the prognosis is gloomy and five-year overall survival is reported to have less than 25%, with regional and distant failure accounting for the majority of the mortality. [ 4 , 5 ] At present multimodality approach with neoadjuvant treatment (Chemotherapy, Radiotherapy or both) followed by surgery with or without adjuvant treatment is considered standard treatment protocol for the management of locally advanced esophageal cancers (LAEC). However, there is no fixed standardized treatment protocol that is followed worldwide and the chemotherapy regimen, dose of radiation, and interval for surgery are followed as per the regional or institutional guidelines, as it still remains unclear whether Neoadjuvant Chemotherapy (NACT) or Neoadjuvant Chemo-radiotherapy (NACRT] is more efficacious in the treatment of locally advanced esophageal cancer. Current data shows that NACRT is associated with an improved pCR (pathological complete response) and R0 resection rate for both the histology; however, the outcome in terms of DFS or OS remains comparable. [ 6 – 12 ] Moreover there is an increased severity of morbidity by the addition of radiation in pre-operative setting. [ 13 , 14 ] The current retrospective study shows the experience of esophageal and gastroesophageal junctional cancer patients operated after neoadjuvant chemotherapy at a single institution, in terms of early surgical outcome i.e. 30-day morbidity/mortality, R0 resection rate and pCR rate. 2. Materials and methods This study was based on a prospectively maintained database of patients who were operated for esophageal and gastroesophageal junctional cancer in the Department of Surgical Oncology, Cancer Research Institute, Swami Rama Himalayan University, Dehradun, Uttarakhand from January 2016 to December 2022. The study was commenced after approval from the Institutional Ethical Committee. All patients operated for esophageal or gastroesophageal junctional cancer were included. Both Adenocarcinoma and Squamous Cell Carcinoma were included. Data regarding neoadjuvant chemotherapy and/or radiotherapy were documented. Patients with inoperable disease and patients who were unable to complete the planned treatment were excluded from the study. Information regarding the patient’s demographics and baseline characteristics, diagnoses, diagnostic procedure and investigation results, medications, neoadjuvant treatment, surgical details, postoperative morbidity, mortality and hospital stay and final pathology report was documented. Before analysis, all the data were anonymized. Data were compiled in an Excel sheet. SPSS version 20 was used for statistical analysis. The primary outcome was thirty-day postoperative morbidity and mortality according to the Esophagectomy Complication Consensus Group (ECCG) [ 15 ] and CTCAE – V5.0 [ 16 ] definition and guidelines. Postoperative complications were compared with previously reported Randomized Control Trials & meta-analyses. 3. Results During the study period total 106 patients were operated, among them 87 patients received preoperative chemotherapy. Out of 106 patients, 21 were excluded due to incomplete data (16 patients) and histology other than SCC and adenocarcinoma (5 patients). Analysis was done on data of rest of the 85 patients. Demographic and baseline characters are shown in Table 1 . In our study 50 (58.8%) patients were male and 35 (41.2%) were female (M:F ratio 1.43: 1). Age of the patients was 55.09 ± 9.90 year (mean ± SD) (range 30–75) and BMI was 20.97 ± 4.42 kg/m 2 (mean ± SD) (range 11.69–30.43) (Table 1 ). Regarding risk factor 19 (22.4%) and 43 (50.6%) patients had a history of alcohol intake and smoking respectively. 36 (42.4%) patients had history of comorbidity of which 10 (11.8%) had h/o diabetes mellitus, 20 (23.5%) had cardiac and 6 (7.1%) had pulmonary disease. Regarding tumor location most of the patients had lower third and GE junction tumor (n = 43, i.e. 50.6%) followed by middle third (n = 39, i.e. 45.9%) and upper third (n = 3, i.e. 3.5%) tumor, whereas histology wise there was mostly squamous cell carcinoma (ESCC) (n = 62; 72.9%) and adenocarcinoma EAC in 23 (27.1%). Table 1 Baseline characteristics n = 85 % Gender Male 50 58.8 Female 35 41.2 Age 30–75 55.09 ± 9.90 BMI 11.69–30.43 20.97 ± 4.42 Preoperative Albumin 3.68 ± 0.61 Addiction Alcoholic 19 22.4 Smoker 43 50.6 Both 5 5.88 Co-morbidities 36 42.4 T2DM 10 11.8 Cardiac 20 23.5 Pulmonary 6 7.1 Others 10 11.8 Location of primary Upper 1/3 3 3.5 Middle 1/3 39 45.9 Lower 1/3 & GEJ 43 50.6 Histopathology Squamous cell carcinoma 23 27.1 Adenocarcinoma 62 72.9 Neoadjuvant Treatment NACT 63 74.1 NACRT 7 8.2 NART 2 2.4 No 13 15.3 Among all patients 72 (84.7%) patients received neoadjuvant therapy and 13 (15.3%) patients underwent upfront surgery. As per our institutional protocol, most patients received a regimen containing a taxane (Paclitaxel 175 mg/m 2 ) and a platinum (Carboplatin AUC 5) as neoadjuvant chemotherapy. Patients with lower esophagus with GEJ (predominantly adenocarcinoma) received mostly FLOT (5Fu, Leucovorin, Oxaliplatin and Docetaxel) & DCF/DCX regimen. For radiotherapy, patients received median doses of 45 Gy in 25 fractions on 6MV Linear accelerator (LINAC) machine by conformal technique. In the neoadjuvant group 63 patients received NACT and 7 patients received NACRT. Most of our patients underwent the Ivor Lewis procedure (2-stage esophagectomy) (50.6%) followed by the McKeown procedure (3-stage esophagectomy) (44.7%). Elective mechanical ventilator support was given to 50.6% of patients until the first postoperative day. The average duration of surgery was 447.29 ± 110.87 min (mean ± SD) (180–810 min) and mean blood loss was 437.53 ± 252.15 ml (mean ± SD) (100–1250 ml), 29 patients (34.1%) received blood transfusions of which 7 (8.2%) patients required ≥ 2 units. (Table 2 ) Table 2 Intraoperative details n % Surgery Ivor Lewis Esophagectomy 43 50.6 McKeown Esophagectomy 38 44.7 Transhiatal Esophagectomy 1 1.2 Others 3 3.5 Duration of surgery (min) 447.29 ± 110.87 Blood loss (ml) 437.53 ± 252.15 Table 3 Perioperative events and complications Present % Absent % Elective ventilation 42 50.6 43 49.4 Hemorrhage 2 2.4 83 97.6 pulmonary complications 16 18.8 69 81.2 Cardiac complications 13 15.3 72 84.7 Enteral feed started D2-3 40 47.1 D4-6 39 45.9 >D6 3 3.53 Wound complications 7 8.2 78 91.8 Anastomotic leak 7 8.2 78 91.8 Reexploration 6 7.1 79 92.6 Mortality 2 2.4 83 97.6 30 Day outcome Discharged 77 90.6 Still in hospital 6 7.1 Death 2 2.4 Clavin Dindo group 0 55 64.71 I 9 10.59 ID 2 2.35 II 11 12.94 IIIA 1 1.18 IIIB 4 4.17 IV 1 1.18 V 2 2.35 We observed morbidity in total 30 patients (35.29%) of which Calvin Dindo grade III/IV complications were in 6 patients (7.08%). Most common complications were nonsurgical, which are respiratory 16 (18.8%) followed by hemodynamic instability/ cardiac morbidity 13 (15.3%) and wound infection 7 (8.2%). Surgical complications such as Anastomotic leak, Reexploration and hemorrhage were observed in 7 (8.2%), 6(7.1%) and 2(2.4%) respectively. 4 patients with anastomotic leak required reexploration and others were managed conservatively; whereas the other 3 patients that were explored in the postoperative period were due to hemorrhage. 2 patients had Calvin Dindo grade I-D morbidity having recurrent laryngeal nerve injury & hoarseness of voice. The overall 30-day outcome was – 77 patients (90.6%) were discharged, 6 patients (7.1%) were still hospitalized and 2 patients (2.4%) expired. Details of operative morbidity and mortality are tabulated in Table 3 . Table 4 Final histopathology n % Tumor pathology ypT0 7 11.11 ypT1 1 1.59 ypT2 24 38.10 ypT3 31 49.21 Tumor pathology ypN0 36 57.14 ypN1 22 34.92 ypN2 4 6.35 ypN3 1 1.59 Pathological complete response 7 11.11 Circumferential margin R0 59 93.65 Number of nodes analyzed (Mean & range) 18.6 (3–70) Number of nodes involved (Mean & range) 1.1 (0–13) Table 4 shows the details of the final pathology report. On analyzing the postoperative histopathology reports we found a complete pathological response in 9 patients (12.5%) and a partial response was seen in 49 (68.6%) patients. The positive margin was seen in 11 patients (12.94), of which CRM was involved in 9 patients and proximal margin positive was in 2 patients. R0 resection was seen in 87.06% patients. In post-NACT group (Table 4 ) CRM was positive in 4 patients and R0 resection was in 93.65% patients, pCR was seen in 7 (11.11%) patients. 4. Discussion Esophageal cancer is one of the most common digestive tract cancers, overall seventh most common cancer and sixth leading cause of cancer-related death worldwide [ 1 ]. It is a disease of the elderly population with a peak incidence in the 7th & 8th decades, although our patients are a decade younger. Equal gender predilection is seen in squamous cell carcinoma (ESCC) but Adenocarcinoma (EAC) is 3–4 times more common in men. In our observation we found an M:F ratio of 1.4:1. Histologically, between the 2 most common types of esophageal cancers, squamous cell carcinoma (ESCC) is more common in Asian countries as in our study also. [ 2 , 3 ] The optimum management of esophageal cancers is a challenging clinical problem still date. Surgery is the main treatment method for resectable disease, but the effectiveness of surgery alone is not satisfactory (local recurrence is as high as 40%-60%, and the 5-year OS rate is less than 30% [ 17 , 18 ]. Hence At present multimodality approach is the standard of care for the management of locally advanced esophageal cancers (LAEC) and surgery is supplemented by Chemotherapy, Radiotherapy or both. The addition of neoadjuvant chemotherapy compared to surgery alone has been shown to increase the R0 resection rate and improve overall survival for both adenocarcinoma and ESCC, though the evidence for the latter is limited. Two important landmark trials The UKMRC OE02 and JCOG9907 trial proved the benefit of NACT and based on the latter preoperative chemotherapy is now the current standard treatment in Japan for LAEC. [ 19 – 26 ] Evidence from the studies that evaluated NACRT also showed an increased rate of R0 resection and better survival benefits compared to surgery alone. Surgery followed by NACRT became the standard of care for LAECs on the basis of results from CROSS and NEOCRTEC5010 trials especially in the western countries. [ 27 – 34 ] Nowadays, a range of neoadjuvant therapy protocols are used globally, including well recognized CROSS, MAGIC, and FLOT regimens. [ 14 , 35 – 37 ] As per our institutional protocol most patients received a regimen containing a taxane (paclitaxel) and a platinum (cisplatin/carboplatin) as neoadjuvant chemotherapy (CROSS trial chemotherapy regimen without radiation). Patients with lower esophagus with GEJ (predominantly adenocarcinoma) received mostly FLOT (5Fu, Leucovorin, Oxaliplatin and Docetaxel) & DCF/DCX regimen. We observed a R0 rate > 80% and pCR of 12.5%. The CROSS trial (EAC = 75%) showed a complete pathological response in 23% patients without any increased postoperative mortality and morbidity in the NACRT group than the surgery group.[ 30 ] The FLOT regimen also demonstrated a significantly improved pCR rate up to 16% [ 26 ]. For ESCC, though there was reported a higher efficacy in the NACRT arm in the CROSS trial (pCR rate: 49%), approximately only one-fourth patients having ESCC, makes it less convincing benefit of ESCC [ 30 , 31 , 32 ]. Previous study reports of CF-based NACT resulted in only 5% pCR rate [ 23 ] whereas recent studies (phase II trial) with docetaxel, cisplatin, and 5-FU (DCF) reported much better results (90.5% R0 resection and pCR rate of 17%) [ 24 , 25 ]. The JCOG1109 NExT trial also demonstrated that the DCF regimen was more efficacious in terms of survival and pCR rate with acceptable toxicity profile. [ 36 , 37 ] Other studies i.e. NEOCRTEC5010, Preoperative therapy in Esophagogastric Adenocarcinoma (POET] and Neoadjuvant Chemotherapy Versus Radio chemotherapy for Cancer of the Esophagus or Cardia (NeoRes) trial also demonstrated a significantly higher R0 rate and pCR rate was 43.2%, 14.3% and 19%. [ 8 – 10 , 33 ]. Results from both clinical trials as well as meta-analyses, it has become evident that the addition of neoadjuvant therapy (CT, RT or both) is more beneficial for locoregional control and survival for esophageal or gastroesophageal junction cancer patients compared to surgery alone or adjuvant therapy [ 6 , 38 , 39 ]. Moreover, irrespective of histological types locally advanced esophageal cancer patients are more likely to achieve R0 resection and pCR after NACRT compared to NACT; however, this finding fails to translate into the improvement of overall survival. [ 6 , 13 , 14 ] The adverse effects of treatments and complications during the perioperative period may contribute to this issue. As per prior reported studies, although there was no significant difference in the frequency of complications after esophagectomy, these are much more severe in the NACRT group than in the NACT group. We collected & documented the morbidity data according to the Esophagectomy complication consensus group (ECCG) [ 15 ] and CTCAE – V5.0 [ 16 ] definition and guidelines. We categorized the morbidities into two main groups - surgical and nonsurgical [ 21 ]. We observed morbidity in a total of 30 patients (35.29%) of which Calvin Dindo grade III/IV complications were in 6 patients (7.08%). [ 40 ] Most common complications were nonsurgical, which are respiratory 16 (18.8%) followed by HD instability/ cardiac morbidity 13 (15.3%) and wound infection 7 (8.2%). Surgical complications such as Anastomotic leak, reexploration and hemorrhage were observed in 7 (8.2%), 6 (7.1%) and 2 (2.4%) respectively. 3 patients with anastomotic leak were managed conservatively whereas 4 patients required exploration. Another 3 patients who were explored in postoperative period were due to hemorrhage. We observed no conduit necrosis or chylothorax in our patients. 2 patients had Calvin Dindo grade I-D morbidity having recurrent laryngeal nerve injury & hoarseness of voice. The overall 30-day outcome was – 77 patients (90.6%) were discharged, 6 patients (7.1%) were still hospitalized and 2 patients (2.4%) expired. Perioperative death, defined as death within 30 days after surgery, occurred in 2 out of 85 patients (2.4%). F. Klevebro et al observed that perioperative mortality was more in the NACRT group (10.2% vs 3.8%) [ 22 ]. Theoretically, the inclusion of radiation therapy to preoperative chemotherapy in the management of esophageal cancer could augment the frequency of postoperative complications. This increase may be attributed to the radiation-induced tissue damage to the nearby organs like the lungs, the heart, and the future gastric conduit. Furthermore, chemotherapy regimens containing taxane are associated with an increased risk of postoperative pulmonary complications. [ 6 , 35 , 38 , 39 ] Although the addition of NACRT did not increase the frequency of postoperative morbidities in the CROSS trial, they were more severe (higher grade) than previously reported studies. In cross study, they reported postoperative pulmonary complications of 46% and anastomotic leak of 22%, which is much higher than our findings [ 30 , 31 , 32 ]. In our study, Post-operative complications were less frequent than in POET and NeoRes trials and other reported evidence also. [ 7 – 10 , 39 ] The strength of our study is that it included a large number of patients from difficult-to-reach sub-Himalayan centers, to best of our knowledge it is the first study to give insight to manage carcinoma esophagus that has much more morbidity and mortality at such centers. Limitations of our study were 1) It was a retrospective nature, 2) Non-randomized type, 3) single center. 5. Conclusions In conclusion, curative esophageal carcinoma surgeries following neoadjuvant chemotherapy are a safe and feasible option as it has acceptable morbidity and mortality. Our study showed excellent pCR (> 11%) and > 93% R0 resection rate with neoadjuvant chemotherapy. However long-term follow-up results are awaited. In our context, where we treat patients from the challenging terrain of the Himalayan region and poor nutritional status, neoadjuvant chemotherapy provides a viable option for better outcomes. However, a properly planned randomized controlled trial would be desirable to draw a meaningful conclusion and our study can provide a basis for the same. Declarations Competing interests : The authors declare that they have no competing interests Funding: No funding was obtained from the private or public sector for this research References GLOBOCAN 2020; International Agency for Research on Cancer 2020; World health organization (https://gco.iarc.fr/today) Huang, J.; Koulaouzidis, A.; Marlicz,W.; Lok, V.; Chu, C.; Ngai, C.H.; Zhang, L.; Chen, P.;Wang, S.; Yuan, J.; et al. Global Burden, Risk Factors, and Trends of Esophageal Cancer: An Analysis of Cancer Registries from 48 Countries. Cancers 2021 , 13, 141. https://doi.org/10.3390/cancers13010141 Vizcaino AP, Moreno V, Lambert R, Parkin DM. Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer. 2002;99(6):860–8. doi:10.1002/ijc.10427. Pohl H, Sirovich B, Welch HG. Esophageal adenocarcinoma incidence: are we reaching the peak? Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2010;19(6):1468–70. doi:10.1158/1055- 9965.EPI-10-0012. Oesophageal Cancer Statistics. Cancer Research UK. http://www.can c e r res e a rchuk.org/health - professional / cancerstatistics/statistics-by-cancer-type/oesophageal-cancer. Accessed 26 September 2022. Zhao X, Ren Y, Hu Y, Cui N, Wang X, Cui Y (2018) Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or the gastroesophageal junction: A meta-analysis based on clinical trials. PLoS ONE 13(8): e0202185. https://doi.org/10.1371/journal. pone.0202185 Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, et al. Phase III Comparison of Preoperative Chemotherapy Compared With Chemoradiotherapy in Patients With Locally Advanced Adenocarcinoma of the Esophagogastric Junction. J Clin Oncol (2009) 27(6):851–6. doi: 10.1200/ JCO.2008.17.0506 Stahl M, Walz MK, Riera-Knorrenschild J, Stuschke M, Sandermann A, Bitzer M, et al. Preoperative Chemotherapy Versus Chemoradiotherapy in Locally Advanced Adenocarcinomas of the Oesophagogastric Junction (POET): Long-Term Results of a Controlled Randomised Trial. Eur J Cancer (2017) 81:183–90. doi: 10.1016/j.ejca.2017.04.027 Klevebro F, Alexandersson von Dobeln G, Wang N, Johnsen G, Jacobsen AB, Friesland S, et al. A Randomized Clinical Trial of Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Cancer of the Oesophagus or Gastro-Oesophageal Junction. Ann Oncol (2016) 27(4):660–7. doi: 10.1093/ annonc/mdw010 von Dobeln GA, Klevebro F, Jacobsen AB, Johannessen HO, Nielsen NH, Johnsen G, et al. Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Cancer of the Esophagus or Gastroesophageal Junction: Long-Term Results of a Randomized Clinical Trial. Dis Esophagus (2019) 32(2):1–11. doi: 10.1093/dote/doy078 Burmeister BH, Thomas JM, Burmeister EA, Walpole ET, Harvey JA, Thomson DB, et al. Is Concurrent Radiation Therapy Required in Patients Receiving Preoperative Chemotherapy for Adenocarcinoma of the Oesophagus? A Randomised Phase II Trial. Eur J Cancer (2011) 47(3):354– 60. doi: 10.1016/j.ejca.2010.09.009 Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated metaanalysis. Lancet Oncol. 2011;12:681-692. Fu T, Bu ZD, Li ZY, Zhang LH, Wu XJ, Wu AW, et al. Neoadjuvant chemoradiation therapy for resectable esophago-gastric adenocarcinoma: a meta-analysis of randomized clinical trials. BMC Cancer. 2015; 15:322. https://doi.org/10.1186/s12885-015-1341-7 PMID: 25928286 Cox, S.J., O’Cathail, S.M., Coles, B. et al. Update on Neoadjuvant Regimens for Patients with Operable Oesophageal/Gastrooesophageal Junction Adenocarcinomas and Squamous Cell Carcinomas. Curr Oncol Rep 19 , 7 (2017). https://doi.org/10.1007/s11912-017-0559-8 Low DE, Alderson D, Cecconello I, Chang AC, Darling GE, D’Journo XB, et al. International consensus on standardization of data collection for complications associated with esophagectomy: esophagectomy complications consensus group (ECCG). Ann Surg 2015;262(2):286–94. https://doi.org/10.1097/ SLA.0000000000001098. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf (Accessed on September 29, 2023). Ohashi S, Miyamoto S, Kikuchi O, Goto T, Amanuma Y, Muto M. Recent Advances From Basic and Clinical Studies of Esophageal Squamous Cell Carcinoma. Gastroenterology. 2015; 149(7):1700±15. https://doi.org/10.1053/j.gastro.2015.08.054 PMID: 26376349 Briasoulis E, Liakakos T, Dova L, Fatouros M, Tsekeris P, Roukos DH, et al. Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther. 2006; 6(6):931±9. https://doi.org/10.1586/14737140.6.6.931 PMID: 16761937 Medical Research Council Oesophageal Cancer Working G. Surgical Resection With or Without Preoperative Chemotherapy in Oesophageal Cancer: A Randomised Controlled Trial. Lancet (2002) 359(9319):1727–33. doi: 10.1016/S0140-6736(02)08651-8 Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative Chemotherapy Versus Surgery Alone for Resectable Gastroesophageal Cancer. N Engl J Med (2006) 355(1):11–20. doi: 10.1056/NEJMoa055531 Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, et al. Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial. J Clin Oncol (2011) 29(13):1715–21. doi: 10.1200/ JCO.2010.33.0597 Kitagawa Y, Ando N, Nakamura K, et al. The role of adjuvant chemotherapy for localized squamous cell esophageal cancer: current Japanese standard and the unending role of the drawing board. Ann Surg Oncol 2012;19:1425–7. Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012; 19(1):68±74. https://doi.org/10.1245/s10434-011-2049-9 PMID: 21879261 Hara H, Tahara M, Daiko H, Kato K, Igaki H, Kadowaki S, et al. Phase II Feasibility Study of Preoperative Chemotherapy With Docetaxel, Cisplatin, and Fluorouracil for Esophageal Squamous Cell Carcinoma. Cancer Sci (2013) 104(11):1455–60. doi: 10.1111/cas.12274 Akiyama Y, Iwaya T, Endo F, Chiba T, Takahara T, Otsuka K, et al. Investigation of Operative Outcomes of Thoracoscopic Esophagectomy After Triplet Chemotherapy With Docetaxel, Cisplatin, and 5-Fluorouracil for Advanced Esophageal Squamous Cell Carcinoma. Surg Endosc (2018) 32 (1):391–9. doi: 10.1007/s00464-017-5688-5 Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative Chemotherapy With Fluorouracil Plus Leucovorin, Oxaliplatin, and Docetaxel Versus Fluorouracil or Capecitabine Plus Cisplatin and Epirubicin for Locally Advanced, Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma (FLOT4): A Randomised, Phase 2/3 Trial. Lancet (2019) 393(10184):1948–57. doi: 10.1016/S0140-6736(18)32557-1 Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, et al. Surgery Alone Versus Chemoradiotherapy Followed by Surgery for Resectable Cancer of the Oesophagus: A Randomised Controlled Phase III Trial. Lancet Oncol (2005) 6(9):659–68. doi: 10.1016/S1470-2045(05)70288-6 Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, et al. Phase III Trial of Trimodality Therapy With Cisplatin, Fluorouracil, Radiotherapy, and Surgery Compared With Surgery Alone for Esophageal Cancer: CALGB 9781. J Clin Oncol (2008) 26(7):1086–92. doi: 10.1200/ JCO.2007.12.9593 Wang DB, Zhang X, Han HL, Xu YJ, Sun DQ, Shi ZL. Neoadjuvant chemoradiotherapy could improve survival outcomes for esophageal carcinoma: a meta-analysis. Dig Dis Sci. 2012; 57(12):3226±33. https://doi.org/10.1007/s10620-012-2263-8 PMID: 22695886 Van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074-2084. https://doi.org/10.1056/NEJMoa1112088 PMID: 22646630 Shapiro J, van Lanschot JJB, Hulshof M, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015; 16(9):1090±8. https://doi.org/10.1016/S1470-2045(15)00040-6 PMID: 26254683 Eyck BM, van Lanschot JJB, Hulshof M, van der Wilk BJ, Shapiro J, van Hagen P, et al. Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial. J Clin Oncol (2021) 39(18):1995–2004. doi: 10.1200/JCO.20.03614 Liu S, Wen J, Yang H, Li Q, Chen Y, Zhu C, et al. Recurrence Patterns After Neoadjuvant Chemoradiotherapy Compared With Surgery Alone in Oesophageal Squamous Cell Carcinoma: Results From the Multicenter Phase III Trial NEOCRTEC5010. Eur J Cancer (2020) 138:113–21.doi: 10.1016/j.ejca.2020.08.002 Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z, et al. Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial. J Clin Oncol (2018) 36(27):2796–803. doi: 10.1200/JCO.2018.79.1483 Shirakawa Y, Noma K, Maeda N, Tanabe S, Sakurama K, Sonoyama-Hanaoka A, et al. Early Intervention of the Perioperative Multidisciplinary Team Approach Decreases the Adverse Events During Neoadjuvant Chemotherapy for Esophageal Cancer Patients. Esophagus (2021) 18 (4):797–805. doi: 10.1007/s10388-021-00844-y Nakamura K, Kato K, Igaki H, Ito Y, Mizusawa J, Ando N, et al. Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study). Jpn J Clin Oncol. 2013; doi:10.1093/jjco/hyt061. Kato K, Ito Y, Daiko H, Ozawa S, Ogata T, Hara H, et al. A Randomized Controlled Phase III Trial Comparing Two Chemotherapy Regimen and Chemoradiotherapy Regimen as Neoadjuvant Treatment for Locally Advanced Esophageal Cancer, JCOG1109 NExT Study. J Clin Oncol (2022) 40(4_suppl):238–. doi: 10.1200/JCO.2022.40.4_suppl.238 Yuan M, Bao Y, Ma Z, Men Y, Wang Y, Hui Z. The Optimal Treatment for Resectable Esophageal Cancer: A Network Meta-Analysis of 6168 Patients. Front Oncol (2021) 11:628706. doi: 10.3389/fonc.2021.628706 Chan KKW, Saluja R, Delos Santos K, Lien K, Shah K, Cramarossa G, et al. Neoadjuvant Treatments for Locally Advanced, Resectable Esophageal Cancer: A Network Meta-Analysis. Int J Cancer (2018) 143(2):430–7. doi: 10.1002/ijc.31312 Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240(2):205–13. https://doi.org/10.1097/01.sla.0000133083.54934.ae. Additional Declarations No competing interests reported. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-3610353","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":249785021,"identity":"ef1c4a25-ff57-4d88-abf1-b806011e3545","order_by":0,"name":"Chiranjit Mukherjee","email":"","orcid":"","institution":"Cancer Research Institute, Swami Rama Himalyan University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Chiranjit","middleName":"","lastName":"Mukherjee","suffix":""},{"id":249785022,"identity":"368f8ce5-d1c1-4bde-a498-ef9544cf6c48","order_by":1,"name":"Sourabh Nandi","email":"","orcid":"","institution":"Cancer Research Institute, Swami Rama Himalyan University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Sourabh","middleName":"","lastName":"Nandi","suffix":""},{"id":249785023,"identity":"35f77822-a31b-464c-8b41-a105b1f18532","order_by":2,"name":"Anshika Arora","email":"","orcid":"","institution":"Cancer Research Institute, Swami Rama Himalyan University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Anshika","middleName":"","lastName":"Arora","suffix":""},{"id":249785024,"identity":"d7a576f3-b71c-42c4-9fac-2a8ad762eb6a","order_by":3,"name":"Sunil Saini","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAAp0lEQVRIiWNgGAWjYFACxsYHDAwHQCwDMCJGS7MBqVoY2CQQWogB/LMPt1X+3HMnsYG9eZsEQ8EdwlokziW23eZ59iyxgedYmQSDwTPCWgx4GNtuMxw4nNggkWMG1HKYOC2FP0Ba5N+QoIWBB2wLD5FaJM4wNksDtRi38aQVWyQQo4W/h/3hR6DDZPvZD2+88eEPEVrggA1EJJCgYRSMglEwCkYBHgAAAso4N72pePEAAAAASUVORK5CYII=","orcid":"","institution":"Cancer Research Institute, Swami Rama Himalyan University","correspondingAuthor":true,"submittingAuthor":false,"prefix":"","firstName":"Sunil","middleName":"","lastName":"Saini","suffix":""},{"id":249785025,"identity":"84857f52-fc37-473c-8f3a-44a9f328353f","order_by":4,"name":"Meenu Gupta","email":"","orcid":"","institution":"Cancer Research Institute, Swami Rama Himalyan University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Meenu","middleName":"","lastName":"Gupta","suffix":""},{"id":249785026,"identity":"489f3a62-0cb9-49d8-a778-2c3aff668cb2","order_by":5,"name":"Shivangi Sundram","email":"","orcid":"","institution":"Cancer Research Institute, Swami Rama Himalyan University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Shivangi","middleName":"","lastName":"Sundram","suffix":""}],"badges":[],"createdAt":"2023-11-14 12:59:14","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-3610353/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-3610353/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":46712632,"identity":"87d85513-b44e-4355-9ed8-69b228982783","added_by":"auto","created_at":"2023-11-18 23:52:22","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":230986,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-3610353/v1/e3c2e77e-de7c-438e-878f-23c0d55a3557.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Early Surgical Outcome of Esophagectomy Performed for Carcinoma Esophagus after Neoadjuvant Chemotherapy – a single center experience from Sub Himalayan region","fulltext":[{"header":"1. Introduction","content":"\u003cp\u003eEsophageal cancer stands out as one of the most aggressive malignancies affecting the digestive tract, representing a prominent contributor to global cancer-related mortality [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]. Despite an overall downward trend in incidence, an increasing trend has been observed in some nations with high incidence ratios of Adenocarcinoma /Squamous Cell Carcinoma (SCC). [\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e, \u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e] Overall the prognosis is gloomy and five-year overall survival is reported to have less than 25%, with regional and distant failure accounting for the majority of the mortality. [\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e]\u003c/p\u003e \u003cp\u003eAt present multimodality approach with neoadjuvant treatment (Chemotherapy, Radiotherapy or both) followed by surgery with or without adjuvant treatment is considered standard treatment protocol for the management of locally advanced esophageal cancers (LAEC). However, there is no fixed standardized treatment protocol that is followed worldwide and the chemotherapy regimen, dose of radiation, and interval for surgery are followed as per the regional or institutional guidelines, as it still remains unclear whether Neoadjuvant Chemotherapy (NACT) or Neoadjuvant Chemo-radiotherapy (NACRT] is more efficacious in the treatment of locally advanced esophageal cancer. Current data shows that NACRT is associated with an improved pCR (pathological complete response) and R0 resection rate for both the histology; however, the outcome in terms of DFS or OS remains comparable. [\u003cspan additionalcitationids=\"CR7 CR8 CR9 CR10 CR11\" citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e] Moreover there is an increased severity of morbidity by the addition of radiation in pre-operative setting. [\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e, \u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e]\u003c/p\u003e \u003cp\u003eThe current retrospective study shows the experience of esophageal and gastroesophageal junctional cancer patients operated after neoadjuvant chemotherapy at a single institution, in terms of early surgical outcome i.e. 30-day morbidity/mortality, R0 resection rate and pCR rate.\u003c/p\u003e"},{"header":"2. Materials and methods","content":"\u003cp\u003eThis study was based on a prospectively maintained database of patients who were operated for esophageal and gastroesophageal junctional cancer in the Department of Surgical Oncology, Cancer Research Institute, Swami Rama Himalayan University, Dehradun, Uttarakhand from January 2016 to December 2022. The study was commenced after approval from the Institutional Ethical Committee. All patients operated for esophageal or gastroesophageal junctional cancer were included. Both Adenocarcinoma and Squamous Cell Carcinoma were included. Data regarding neoadjuvant chemotherapy and/or radiotherapy were documented. Patients with inoperable disease and patients who were unable to complete the planned treatment were excluded from the study.\u003c/p\u003e \u003cp\u003eInformation regarding the patient\u0026rsquo;s demographics and baseline characteristics, diagnoses, diagnostic procedure and investigation results, medications, neoadjuvant treatment, surgical details, postoperative morbidity, mortality and hospital stay and final pathology report was documented. Before analysis, all the data were anonymized. Data were compiled in an Excel sheet. SPSS version 20 was used for statistical analysis.\u003c/p\u003e \u003cp\u003eThe primary outcome was thirty-day postoperative morbidity and mortality according to the Esophagectomy Complication Consensus Group (ECCG) [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e] and CTCAE \u0026ndash; V5.0 [\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e] definition and guidelines. Postoperative complications were compared with previously reported Randomized Control Trials \u0026amp; meta-analyses.\u003c/p\u003e"},{"header":"3. Results","content":"\u003cp\u003eDuring the study period total 106 patients were operated, among them 87 patients received preoperative chemotherapy. Out of 106 patients, 21 were excluded due to incomplete data (16 patients) and histology other than SCC and adenocarcinoma (5 patients). Analysis was done on data of rest of the 85 patients. Demographic and baseline characters are shown in Table \u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e. In our study 50 (58.8%) patients were male and 35 (41.2%) were female (M:F ratio 1.43: 1). Age of the patients was 55.09\u0026thinsp;\u0026plusmn;\u0026thinsp;9.90 year (mean\u0026thinsp;\u0026plusmn;\u0026thinsp;SD) (range 30\u0026ndash;75) and BMI was 20.97\u0026thinsp;\u0026plusmn;\u0026thinsp;4.42 kg/m\u003csup\u003e2\u003c/sup\u003e (mean\u0026thinsp;\u0026plusmn;\u0026thinsp;SD) (range 11.69\u0026ndash;30.43) (Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e). Regarding risk factor 19 (22.4%) and 43 (50.6%) patients had a history of alcohol intake and smoking respectively. 36 (42.4%) patients had history of comorbidity of which 10 (11.8%) had h/o diabetes mellitus, 20 (23.5%) had cardiac and 6 (7.1%) had pulmonary disease. Regarding tumor location most of the patients had lower third and GE junction tumor (n\u0026thinsp;=\u0026thinsp;43, i.e. 50.6%) followed by middle third (n\u0026thinsp;=\u0026thinsp;39, i.e. 45.9%) and upper third (n\u0026thinsp;=\u0026thinsp;3, i.e. 3.5%) tumor, whereas histology wise there was mostly squamous cell carcinoma (ESCC) (n\u0026thinsp;=\u0026thinsp;62; 72.9%) and adenocarcinoma EAC in 23 (27.1%).\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eBaseline characteristics\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"3\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003en\u0026thinsp;=\u0026thinsp;85\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003e%\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eGender\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e50\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e58.8\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eFemale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e35\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e41.2\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAge\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e30\u0026ndash;75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e55.09\u0026thinsp;\u0026plusmn;\u0026thinsp;9.90\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBMI\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e11.69\u0026ndash;30.43\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e20.97\u0026thinsp;\u0026plusmn;\u0026thinsp;4.42\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePreoperative Albumin\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e3.68\u0026thinsp;\u0026plusmn;\u0026thinsp;0.61\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAddiction\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAlcoholic\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e19\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e22.4\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSmoker\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e43\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e50.6\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBoth\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e5.88\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCo-morbidities\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e36\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e42.4\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eT2DM\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e10\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e11.8\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCardiac\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e20\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e23.5\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePulmonary\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e7.1\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eOthers\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e10\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e11.8\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLocation of primary\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eUpper 1/3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e3.5\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMiddle 1/3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e39\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e45.9\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLower 1/3 \u0026amp; GEJ\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e43\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e50.6\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHistopathology\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSquamous cell carcinoma\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e23\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e27.1\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAdenocarcinoma\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e62\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e72.9\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNeoadjuvant Treatment\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNACT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e63\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e74.1\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNACRT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e8.2\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNART\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e2.4\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e13\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e15.3\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003eAmong all patients 72 (84.7%) patients received neoadjuvant therapy and 13 (15.3%) patients underwent upfront surgery. As per our institutional protocol, most patients received a regimen containing a taxane (Paclitaxel 175 mg/m\u003csup\u003e2\u003c/sup\u003e) and a platinum (Carboplatin AUC 5) as neoadjuvant chemotherapy. Patients with lower esophagus with GEJ (predominantly adenocarcinoma) received mostly FLOT (5Fu, Leucovorin, Oxaliplatin and Docetaxel) \u0026amp; DCF/DCX regimen. For radiotherapy, patients received median doses of 45 Gy in 25 fractions on 6MV Linear accelerator (LINAC) machine by conformal technique.\u003c/p\u003e \u003cp\u003eIn the neoadjuvant group 63 patients received NACT and 7 patients received NACRT. Most of our patients underwent the Ivor Lewis procedure (2-stage esophagectomy) (50.6%) followed by the McKeown procedure (3-stage esophagectomy) (44.7%). Elective mechanical ventilator support was given to 50.6% of patients until the first postoperative day. The average duration of surgery was 447.29\u0026thinsp;\u0026plusmn;\u0026thinsp;110.87 min (mean\u0026thinsp;\u0026plusmn;\u0026thinsp;SD) (180\u0026ndash;810 min) and mean blood loss was 437.53\u0026thinsp;\u0026plusmn;\u0026thinsp;252.15 ml (mean\u0026thinsp;\u0026plusmn;\u0026thinsp;SD) (100\u0026ndash;1250 ml), 29 patients (34.1%) received blood transfusions of which 7 (8.2%) patients required\u0026thinsp;\u0026ge;\u0026thinsp;2 units. (Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e)\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab2\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eIntraoperative details\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"3\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003en\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003e%\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSurgery\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eIvor Lewis Esophagectomy\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e43\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e50.6\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMcKeown Esophagectomy\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e38\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e44.7\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eTranshiatal Esophagectomy\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e1.2\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eOthers\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e3.5\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDuration of surgery (min)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e447.29\u0026thinsp;\u0026plusmn;\u0026thinsp;110.87\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBlood loss (ml)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e437.53\u0026thinsp;\u0026plusmn;\u0026thinsp;252.15\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab3\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 3\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003ePerioperative events and complications\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"5\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePresent\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003e%\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eAbsent\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003e%\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eElective ventilation\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e42\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e50.6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e43\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e49.4\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHemorrhage\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e2.4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e83\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e97.6\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003epulmonary complications\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e16\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e18.8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e69\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e81.2\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCardiac complications\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e13\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e15.3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e72\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e84.7\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eEnteral feed started\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eD2-3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e40\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e47.1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eD4-6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e39\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e45.9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u0026gt;D6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e3.53\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eWound complications\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e8.2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e78\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e91.8\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAnastomotic leak\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e8.2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e78\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e91.8\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eReexploration\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e7.1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e79\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e92.6\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMortality\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e2.4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e83\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e97.6\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e30 Day outcome\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDischarged\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e77\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e90.6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eStill in hospital\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e7.1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDeath\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e2.4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eClavin Dindo group\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e55\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e64.71\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eI\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e10.59\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eID\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e2.35\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eII\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e11\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e12.94\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eIIIA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e1.18\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eIIIB\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e4.17\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eIV\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e1.18\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eV\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e2.35\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003eWe observed morbidity in total 30 patients (35.29%) of which Calvin Dindo grade III/IV complications were in 6 patients (7.08%). Most common complications were nonsurgical, which are respiratory 16 (18.8%) followed by hemodynamic instability/ cardiac morbidity 13 (15.3%) and wound infection 7 (8.2%). Surgical complications such as Anastomotic leak, Reexploration and hemorrhage were observed in 7 (8.2%), 6(7.1%) and 2(2.4%) respectively. 4 patients with anastomotic leak required reexploration and others were managed conservatively; whereas the other 3 patients that were explored in the postoperative period were due to hemorrhage. 2 patients had Calvin Dindo grade I-D morbidity having recurrent laryngeal nerve injury \u0026amp; hoarseness of voice. The overall 30-day outcome was \u0026ndash; 77 patients (90.6%) were discharged, 6 patients (7.1%) were still hospitalized and 2 patients (2.4%) expired. Details of operative morbidity and mortality are tabulated in Table\u0026nbsp;\u003cspan refid=\"Tab3\" class=\"InternalRef\"\u003e3\u003c/span\u003e.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab4\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 4\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eFinal histopathology\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"3\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003en\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003e%\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eTumor pathology\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eypT0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e11.11\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eypT1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e1.59\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eypT2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e24\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e38.10\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eypT3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e31\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e49.21\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eTumor pathology\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eypN0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e36\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e57.14\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eypN1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e22\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e34.92\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eypN2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e6.35\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eypN3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e1.59\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePathological complete response\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e11.11\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCircumferential margin R0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e59\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e93.65\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNumber of nodes analyzed (Mean \u0026amp; range)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e18.6 (3\u0026ndash;70)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNumber of nodes involved (Mean \u0026amp; range)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.1 (0\u0026ndash;13)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003eTable\u0026nbsp;\u003cspan refid=\"Tab4\" class=\"InternalRef\"\u003e4\u003c/span\u003e shows the details of the final pathology report. On analyzing the postoperative histopathology reports we found a complete pathological response in 9 patients (12.5%) and a partial response was seen in 49 (68.6%) patients. The positive margin was seen in 11 patients (12.94), of which CRM was involved in 9 patients and proximal margin positive was in 2 patients. R0 resection was seen in 87.06% patients. In post-NACT group (Table\u0026nbsp;\u003cspan refid=\"Tab4\" class=\"InternalRef\"\u003e4\u003c/span\u003e) CRM was positive in 4 patients and R0 resection was in 93.65% patients, pCR was seen in 7 (11.11%) patients.\u003c/p\u003e"},{"header":"4. Discussion","content":"\u003cp\u003eEsophageal cancer is one of the most common digestive tract cancers, overall seventh most common cancer and sixth leading cause of cancer-related death worldwide [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]. It is a disease of the elderly population with a peak incidence in the 7th \u0026amp; 8th decades, although our patients are a decade younger. Equal gender predilection is seen in squamous cell carcinoma (ESCC) but Adenocarcinoma (EAC) is 3\u0026ndash;4 times more common in men. In our observation we found an M:F ratio of 1.4:1. Histologically, between the 2 most common types of esophageal cancers, squamous cell carcinoma (ESCC) is more common in Asian countries as in our study also. [\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e, \u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e]\u003c/p\u003e \u003cp\u003eThe optimum management of esophageal cancers is a challenging clinical problem still date. Surgery is the main treatment method for resectable disease, but the effectiveness of surgery alone is not satisfactory (local recurrence is as high as 40%-60%, and the 5-year OS rate is less than 30% [\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e, \u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eHence At present multimodality approach is the standard of care for the management of locally advanced esophageal cancers (LAEC) and surgery is supplemented by Chemotherapy, Radiotherapy or both. The addition of neoadjuvant chemotherapy compared to surgery alone has been shown to increase the R0 resection rate and improve overall survival for both adenocarcinoma and ESCC, though the evidence for the latter is limited. Two important landmark trials The UKMRC OE02 and JCOG9907 trial proved the benefit of NACT and based on the latter preoperative chemotherapy is now the current standard treatment in Japan for LAEC. [\u003cspan additionalcitationids=\"CR20 CR21 CR22 CR23 CR24 CR25\" citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e]\u003c/p\u003e \u003cp\u003eEvidence from the studies that evaluated NACRT also showed an increased rate of R0 resection and better survival benefits compared to surgery alone. Surgery followed by NACRT became the standard of care for LAECs on the basis of results from CROSS and NEOCRTEC5010 trials especially in the western countries. [\u003cspan additionalcitationids=\"CR28 CR29 CR30 CR31 CR32 CR33\" citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e]\u003c/p\u003e \u003cp\u003eNowadays, a range of neoadjuvant therapy protocols are used globally, including well recognized CROSS, MAGIC, and FLOT regimens. [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e, \u003cspan additionalcitationids=\"CR36\" citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e] As per our institutional protocol most patients received a regimen containing a taxane (paclitaxel) and a platinum (cisplatin/carboplatin) as neoadjuvant chemotherapy (CROSS trial chemotherapy regimen without radiation). Patients with lower esophagus with GEJ (predominantly adenocarcinoma) received mostly FLOT (5Fu, Leucovorin, Oxaliplatin and Docetaxel) \u0026amp; DCF/DCX regimen. We observed a R0 rate\u0026thinsp;\u0026gt;\u0026thinsp;80% and pCR of 12.5%.\u003c/p\u003e \u003cp\u003eThe CROSS trial (EAC\u0026thinsp;=\u0026thinsp;75%) showed a complete pathological response in 23% patients without any increased postoperative mortality and morbidity in the NACRT group than the surgery group.[\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e] The FLOT regimen also demonstrated a significantly improved pCR rate up to 16% [\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eFor ESCC, though there was reported a higher efficacy in the NACRT arm in the CROSS trial (pCR rate: 49%), approximately only one-fourth patients having ESCC, makes it less convincing benefit of ESCC [\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e, \u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e, \u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e]. Previous study reports of CF-based NACT resulted in only 5% pCR rate [\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e] whereas recent studies (phase II trial) with docetaxel, cisplatin, and 5-FU (DCF) reported much better results (90.5% R0 resection and pCR rate of 17%) [\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e, \u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e]. The JCOG1109 NExT trial also demonstrated that the DCF regimen was more efficacious in terms of survival and pCR rate with acceptable toxicity profile. [\u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e, \u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e] Other studies i.e. NEOCRTEC5010, Preoperative therapy in Esophagogastric Adenocarcinoma (POET] and Neoadjuvant Chemotherapy Versus Radio chemotherapy for Cancer of the Esophagus or Cardia (NeoRes) trial also demonstrated a significantly higher R0 rate and pCR rate was 43.2%, 14.3% and 19%. [\u003cspan additionalcitationids=\"CR9\" citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e, \u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eResults from both clinical trials as well as meta-analyses, it has become evident that the addition of neoadjuvant therapy (CT, RT or both) is more beneficial for locoregional control and survival for esophageal or gastroesophageal junction cancer patients compared to surgery alone or adjuvant therapy [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e, \u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e, \u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e]. Moreover, irrespective of histological types locally advanced esophageal cancer patients are more likely to achieve R0 resection and pCR after NACRT compared to NACT; however, this finding fails to translate into the improvement of overall survival. [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e, \u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e, \u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e] The adverse effects of treatments and complications during the perioperative period may contribute to this issue.\u003c/p\u003e \u003cp\u003eAs per prior reported studies, although there was no significant difference in the frequency of complications after esophagectomy, these are much more severe in the NACRT group than in the NACT group. We collected \u0026amp; documented the morbidity data according to the Esophagectomy complication consensus group (ECCG) [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e] and CTCAE \u0026ndash; V5.0 [\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e] definition and guidelines. We categorized the morbidities into two main groups - surgical and nonsurgical [\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e]. We observed morbidity in a total of 30 patients (35.29%) of which Calvin Dindo grade III/IV complications were in 6 patients (7.08%). [\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e] Most common complications were nonsurgical, which are respiratory 16 (18.8%) followed by HD instability/ cardiac morbidity 13 (15.3%) and wound infection 7 (8.2%). Surgical complications such as Anastomotic leak, reexploration and hemorrhage were observed in 7 (8.2%), 6 (7.1%) and 2 (2.4%) respectively. 3 patients with anastomotic leak were managed conservatively whereas 4 patients required exploration. Another 3 patients who were explored in postoperative period were due to hemorrhage. We observed no conduit necrosis or chylothorax in our patients. 2 patients had Calvin Dindo grade I-D morbidity having recurrent laryngeal nerve injury \u0026amp; hoarseness of voice.\u003c/p\u003e \u003cp\u003eThe overall 30-day outcome was \u0026ndash; 77 patients (90.6%) were discharged, 6 patients (7.1%) were still hospitalized and 2 patients (2.4%) expired. Perioperative death, defined as death within 30 days after surgery, occurred in 2 out of 85 patients (2.4%). F. Klevebro et al observed that perioperative mortality was more in the NACRT group (10.2% vs 3.8%) [\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eTheoretically, the inclusion of radiation therapy to preoperative chemotherapy in the management of esophageal cancer could augment the frequency of postoperative complications. This increase may be attributed to the radiation-induced tissue damage to the nearby organs like the lungs, the heart, and the future gastric conduit. Furthermore, chemotherapy regimens containing taxane are associated with an increased risk of postoperative pulmonary complications. [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e, \u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e, \u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e, \u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e]\u003c/p\u003e \u003cp\u003eAlthough the addition of NACRT did not increase the frequency of postoperative morbidities in the CROSS trial, they were more severe (higher grade) than previously reported studies. In cross study, they reported postoperative pulmonary complications of 46% and anastomotic leak of 22%, which is much higher than our findings [\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e, \u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e, \u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e]. In our study, Post-operative complications were less frequent than in POET and NeoRes trials and other reported evidence also. [\u003cspan additionalcitationids=\"CR8 CR9\" citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e, \u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e]\u003c/p\u003e \u003cp\u003eThe strength of our study is that it included a large number of patients from difficult-to-reach sub-Himalayan centers, to best of our knowledge it is the first study to give insight to manage carcinoma esophagus that has much more morbidity and mortality at such centers. Limitations of our study were 1) It was a retrospective nature, 2) Non-randomized type, 3) single center.\u003c/p\u003e"},{"header":"5. Conclusions","content":"\u003cp\u003eIn conclusion, curative esophageal carcinoma surgeries following neoadjuvant chemotherapy are a safe and feasible option as it has acceptable morbidity and mortality. Our study showed excellent pCR (\u0026gt;\u0026thinsp;11%) and \u0026gt;\u0026thinsp;93% R0 resection rate with neoadjuvant chemotherapy. However long-term follow-up results are awaited. In our context, where we treat patients from the challenging terrain of the Himalayan region and poor nutritional status, neoadjuvant chemotherapy provides a viable option for better outcomes. However, a properly planned randomized controlled trial would be desirable to draw a meaningful conclusion and our study can provide a basis for the same.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eCompeting interests\u003c/strong\u003e: The authors declare that they have no competing interests\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding: No funding was obtained from the private or public sector for this research\u003c/strong\u003e\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eGLOBOCAN 2020; International Agency for Research on Cancer 2020; World health organization (https://gco.iarc.fr/today)\u003c/li\u003e\n\u003cli\u003eHuang, J.; Koulaouzidis, A.; Marlicz,W.; Lok, V.; Chu, C.; Ngai, C.H.; Zhang, L.; Chen, P.;Wang, S.; Yuan, J.; et al. Global Burden, Risk Factors, and Trends of Esophageal Cancer: An Analysis of Cancer Registries from 48 Countries. Cancers \u003cstrong\u003e2021\u003c/strong\u003e, 13, 141. https://doi.org/10.3390/cancers13010141 \u003c/li\u003e\n\u003cli\u003eVizcaino AP, Moreno V, Lambert R, Parkin DM. Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer. 2002;99(6):860\u0026ndash;8. doi:10.1002/ijc.10427.\u003c/li\u003e\n\u003cli\u003ePohl H, Sirovich B, Welch HG. Esophageal adenocarcinoma incidence: are we reaching the peak? Cancer epidemiology, biomarkers \u0026amp; prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2010;19(6):1468\u0026ndash;70. doi:10.1158/1055- 9965.EPI-10-0012.\u003c/li\u003e\n\u003cli\u003eOesophageal Cancer Statistics. Cancer Research UK. http://www.can c e r res e a rchuk.org/health - professional / cancerstatistics/statistics-by-cancer-type/oesophageal-cancer. Accessed 26 September 2022.\u003c/li\u003e\n\u003cli\u003eZhao X, Ren Y, Hu Y, Cui N, Wang X, Cui Y (2018) Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or the gastroesophageal junction: A meta-analysis based on clinical trials. PLoS ONE 13(8): e0202185. https://doi.org/10.1371/journal. pone.0202185\u003c/li\u003e\n\u003cli\u003eStahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, et al. Phase III Comparison of Preoperative Chemotherapy Compared With Chemoradiotherapy in Patients With Locally Advanced Adenocarcinoma of the Esophagogastric Junction. J Clin Oncol (2009) 27(6):851\u0026ndash;6. doi: 10.1200/ JCO.2008.17.0506\u003c/li\u003e\n\u003cli\u003eStahl M, Walz MK, Riera-Knorrenschild J, Stuschke M, Sandermann A, Bitzer M, et al. Preoperative Chemotherapy Versus Chemoradiotherapy in Locally Advanced Adenocarcinomas of the Oesophagogastric Junction (POET): Long-Term Results of a Controlled Randomised Trial. Eur J Cancer (2017) 81:183\u0026ndash;90. doi: 10.1016/j.ejca.2017.04.027\u003c/li\u003e\n\u003cli\u003eKlevebro F, Alexandersson von Dobeln G, Wang N, Johnsen G, Jacobsen AB, Friesland S, et al. A Randomized Clinical Trial of Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Cancer of the Oesophagus or Gastro-Oesophageal Junction. Ann Oncol (2016) 27(4):660\u0026ndash;7. doi: 10.1093/ annonc/mdw010\u003c/li\u003e\n\u003cli\u003evon Dobeln GA, Klevebro F, Jacobsen AB, Johannessen HO, Nielsen NH, Johnsen G, et al. Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Cancer of the Esophagus or Gastroesophageal Junction: Long-Term Results of a Randomized Clinical Trial. Dis Esophagus (2019) 32(2):1\u0026ndash;11. doi: 10.1093/dote/doy078\u003c/li\u003e\n\u003cli\u003eBurmeister BH, Thomas JM, Burmeister EA, Walpole ET, Harvey JA, Thomson DB, et al. Is Concurrent Radiation Therapy Required in Patients Receiving Preoperative Chemotherapy for Adenocarcinoma of the Oesophagus? A Randomised Phase II Trial. Eur J Cancer (2011) 47(3):354\u0026ndash; 60. doi: 10.1016/j.ejca.2010.09.009\u003c/li\u003e\n\u003cli\u003eSjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated metaanalysis. Lancet Oncol. 2011;12:681-692.\u003c/li\u003e\n\u003cli\u003eFu T, Bu ZD, Li ZY, Zhang LH, Wu XJ, Wu AW, et al. Neoadjuvant chemoradiation therapy for resectable esophago-gastric adenocarcinoma: a meta-analysis of randomized clinical trials. BMC Cancer. 2015; 15:322. https://doi.org/10.1186/s12885-015-1341-7 PMID: 25928286\u003c/li\u003e\n\u003cli\u003eCox, S.J., O\u0026rsquo;Cathail, S.M., Coles, B. \u003cem\u003eet al.\u003c/em\u003e Update on Neoadjuvant Regimens for Patients with Operable Oesophageal/Gastrooesophageal Junction Adenocarcinomas and Squamous Cell Carcinomas. \u003cem\u003eCurr Oncol Rep\u003c/em\u003e\u003cstrong\u003e19\u003c/strong\u003e, 7 (2017). https://doi.org/10.1007/s11912-017-0559-8\u003c/li\u003e\n\u003cli\u003eLow DE, Alderson D, Cecconello I, Chang AC, Darling GE, D\u0026rsquo;Journo XB, et al. International consensus on standardization of data collection for complications associated with esophagectomy: esophagectomy complications consensus group (ECCG). Ann Surg 2015;262(2):286\u0026ndash;94. https://doi.org/10.1097/ SLA.0000000000001098.\u003c/li\u003e\n\u003cli\u003ehttps://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf (Accessed on September 29, 2023).\u003c/li\u003e\n\u003cli\u003eOhashi S, Miyamoto S, Kikuchi O, Goto T, Amanuma Y, Muto M. Recent Advances From Basic and Clinical Studies of Esophageal Squamous Cell Carcinoma. Gastroenterology. 2015; 149(7):1700\u0026plusmn;15. https://doi.org/10.1053/j.gastro.2015.08.054 PMID: 26376349\u003c/li\u003e\n\u003cli\u003eBriasoulis E, Liakakos T, Dova L, Fatouros M, Tsekeris P, Roukos DH, et al. Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther. 2006; 6(6):931\u0026plusmn;9. https://doi.org/10.1586/14737140.6.6.931 PMID: 16761937\u003c/li\u003e\n\u003cli\u003eMedical Research Council Oesophageal Cancer Working G. Surgical Resection With or Without Preoperative Chemotherapy in Oesophageal Cancer: A Randomised Controlled Trial. Lancet (2002) 359(9319):1727\u0026ndash;33. doi: 10.1016/S0140-6736(02)08651-8\u003c/li\u003e\n\u003cli\u003eCunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative Chemotherapy Versus Surgery Alone for Resectable Gastroesophageal Cancer. N Engl J Med (2006) 355(1):11\u0026ndash;20. doi: 10.1056/NEJMoa055531\u003c/li\u003e\n\u003cli\u003eYchou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, et al. Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial. J Clin Oncol (2011) 29(13):1715\u0026ndash;21. doi: 10.1200/ JCO.2010.33.0597\u003c/li\u003e\n\u003cli\u003eKitagawa Y, Ando N, Nakamura K, et al. The role of adjuvant chemotherapy for localized squamous cell esophageal cancer: current Japanese standard and the unending role of the drawing board. Ann Surg Oncol 2012;19:1425\u0026ndash;7.\u003c/li\u003e\n\u003cli\u003eAndo N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012; 19(1):68\u0026plusmn;74. https://doi.org/10.1245/s10434-011-2049-9 PMID: 21879261\u003c/li\u003e\n\u003cli\u003eHara H, Tahara M, Daiko H, Kato K, Igaki H, Kadowaki S, et al. Phase II Feasibility Study of Preoperative Chemotherapy With Docetaxel, Cisplatin, and Fluorouracil for Esophageal Squamous Cell Carcinoma. Cancer Sci (2013) 104(11):1455\u0026ndash;60. doi: 10.1111/cas.12274\u003c/li\u003e\n\u003cli\u003eAkiyama Y, Iwaya T, Endo F, Chiba T, Takahara T, Otsuka K, et al. Investigation of Operative Outcomes of Thoracoscopic Esophagectomy After Triplet Chemotherapy With Docetaxel, Cisplatin, and 5-Fluorouracil for Advanced Esophageal Squamous Cell Carcinoma. Surg Endosc (2018) 32 (1):391\u0026ndash;9. doi: 10.1007/s00464-017-5688-5 \u003c/li\u003e\n\u003cli\u003eAl-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative Chemotherapy With Fluorouracil Plus Leucovorin, Oxaliplatin, and Docetaxel Versus Fluorouracil or Capecitabine Plus Cisplatin and Epirubicin for Locally Advanced, Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma (FLOT4): A Randomised, Phase 2/3 Trial. Lancet (2019) 393(10184):1948\u0026ndash;57. doi: 10.1016/S0140-6736(18)32557-1\u003c/li\u003e\n\u003cli\u003eBurmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, et al. Surgery Alone Versus Chemoradiotherapy Followed by Surgery for Resectable Cancer of the Oesophagus: A Randomised Controlled Phase III Trial. Lancet Oncol (2005) 6(9):659\u0026ndash;68. doi: 10.1016/S1470-2045(05)70288-6\u003c/li\u003e\n\u003cli\u003eTepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, et al. Phase III Trial of Trimodality Therapy With Cisplatin, Fluorouracil, Radiotherapy, and Surgery Compared With Surgery Alone for Esophageal Cancer: CALGB 9781. J Clin Oncol (2008) 26(7):1086\u0026ndash;92. doi: 10.1200/ JCO.2007.12.9593\u003c/li\u003e\n\u003cli\u003eWang DB, Zhang X, Han HL, Xu YJ, Sun DQ, Shi ZL. Neoadjuvant chemoradiotherapy could improve survival outcomes for esophageal carcinoma: a meta-analysis. Dig Dis Sci. 2012; 57(12):3226\u0026plusmn;33. https://doi.org/10.1007/s10620-012-2263-8 PMID: 22695886\u003c/li\u003e\n\u003cli\u003eVan Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074-2084. https://doi.org/10.1056/NEJMoa1112088 PMID: 22646630\u003c/li\u003e\n\u003cli\u003eShapiro J, van Lanschot JJB, Hulshof M, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015; 16(9):1090\u0026plusmn;8. https://doi.org/10.1016/S1470-2045(15)00040-6 PMID: 26254683\u003c/li\u003e\n\u003cli\u003eEyck BM, van Lanschot JJB, Hulshof M, van der Wilk BJ, Shapiro J, van Hagen P, et al. Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial. J Clin Oncol (2021) 39(18):1995\u0026ndash;2004. doi: 10.1200/JCO.20.03614\u003c/li\u003e\n\u003cli\u003eLiu S, Wen J, Yang H, Li Q, Chen Y, Zhu C, et al. Recurrence Patterns After Neoadjuvant Chemoradiotherapy Compared With Surgery Alone in Oesophageal Squamous Cell Carcinoma: Results From the Multicenter Phase III Trial NEOCRTEC5010. Eur J Cancer (2020) 138:113\u0026ndash;21.doi: 10.1016/j.ejca.2020.08.002\u003c/li\u003e\n\u003cli\u003eYang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z, et al. Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial. J Clin Oncol (2018) 36(27):2796\u0026ndash;803. doi: 10.1200/JCO.2018.79.1483\u003c/li\u003e\n\u003cli\u003eShirakawa Y, Noma K, Maeda N, Tanabe S, Sakurama K, Sonoyama-Hanaoka A, et al. Early Intervention of the Perioperative Multidisciplinary Team Approach Decreases the Adverse Events During Neoadjuvant Chemotherapy for Esophageal Cancer Patients. Esophagus (2021) 18 (4):797\u0026ndash;805. doi: 10.1007/s10388-021-00844-y\u003c/li\u003e\n\u003cli\u003eNakamura K, Kato K, Igaki H, Ito Y, Mizusawa J, Ando N, et al. Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study). Jpn J Clin Oncol. 2013; doi:10.1093/jjco/hyt061.\u003c/li\u003e\n\u003cli\u003eKato K, Ito Y, Daiko H, Ozawa S, Ogata T, Hara H, et al. A Randomized Controlled Phase III Trial Comparing Two Chemotherapy Regimen and Chemoradiotherapy Regimen as Neoadjuvant Treatment for Locally Advanced Esophageal Cancer, JCOG1109 NExT Study. J Clin Oncol (2022) 40(4_suppl):238\u0026ndash;. doi: 10.1200/JCO.2022.40.4_suppl.238\u003c/li\u003e\n\u003cli\u003eYuan M, Bao Y, Ma Z, Men Y, Wang Y, Hui Z. The Optimal Treatment for Resectable Esophageal Cancer: A Network Meta-Analysis of 6168 Patients. Front Oncol (2021) 11:628706. doi: 10.3389/fonc.2021.628706\u003c/li\u003e\n\u003cli\u003eChan KKW, Saluja R, Delos Santos K, Lien K, Shah K, Cramarossa G, et al. Neoadjuvant Treatments for Locally Advanced, Resectable Esophageal Cancer: A Network Meta-Analysis. Int J Cancer (2018) 143(2):430\u0026ndash;7. doi: 10.1002/ijc.31312\u003c/li\u003e\n\u003cli\u003eDindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240(2):205\u0026ndash;13. https://doi.org/10.1097/01.sla.0000133083.54934.ae. \u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"","lastPublishedDoi":"10.21203/rs.3.rs-3610353/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-3610353/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eEsophageal cancer poses a significant global health burden, characterized by high aggressiveness and mortality rates. Despite a decline in overall incidence, certain regions exhibit a rise of adenocarcinoma incidence. At present multimodality approach with neoadjuvant treatment (Chemotherapy, Radiotherapy or both) followed by surgery with or without adjuvant treatment is standard of care, although there is no standard protocol. This retrospective, conducted at a tertiary center in the Himalayan region, explores the outcomes of esophageal and gastroesophageal junctional cancer patients undergoing surgery following neoadjuvant chemotherapy.\u003c/p\u003e \u003cp\u003eAmong 106 patients, 87 received preoperative chemotherapy, with demographic data revealing a male predominance and prevalent squamous cell carcinoma histology. Neoadjuvant therapy mainly comprised taxane-platinum regimens, with subsequent surgical procedures predominantly Ivor Lewis or McKeown esophagectomies. 30-day morbidity and mortality were observed in 35.29% of cases, with nonsurgical complications, particularly respiratory issues, being the most common. Our study reported a complete pathological response in 12.5% cases and an R0 resection rate exceeding 93%.\u003c/p\u003e \u003cp\u003eWhile acknowledging the study\u0026rsquo;s retrospective and non-randomized nature, these findings suggest that neoadjuvant chemotherapy facilitates safe esophageal cancer surgeries specifically in undernourished patients.\u003c/p\u003e","manuscriptTitle":"Early Surgical Outcome of Esophagectomy Performed for Carcinoma Esophagus after Neoadjuvant Chemotherapy – a single center experience from Sub Himalayan region","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2023-11-17 12:12:55","doi":"10.21203/rs.3.rs-3610353/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"55632d92-7c38-4c48-810d-6871eceb3933","owner":[],"postedDate":"November 17th, 2023","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2023-11-18T23:44:15+00:00","versionOfRecord":[],"versionCreatedAt":"2023-11-17 12:12:55","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-3610353","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-3610353","identity":"rs-3610353","version":["v1"]},"buildId":"rHA-KDH7Qsr4HCuvH75dn","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}